Antilymphocyte globulin for prevention of chronic graft-versus-host disease

New England Journal of Medicine

Volumn 374, Issue 1, 2016, Pages 43-53

  Kröger, Nicolaus ^a   Solano, Carlos ^e   Wolschke, Christine ^a   Bandini, Giuseppe ^k   Patriarca, Francesca ^l   Pini, Massimo ^m   Nagler, Arnon ^ab   Selleri, Carmine ^n,aa   Risitano, Antonio ⁿ   Messina, Giuseppe ^o   Bethge, Wolfgang ^c   De Oteiza, Jaime Pérez ^f   Duarte, Rafael ^g   Carella, Angelo Michele ^p   Cimminiello, Michele ^q   Guidi, Stefano ^r   Finke, Jürgen ^b   Mordini, Nicola ^s   Ferra, Christelle ^h   Sierra, Jorge ⁱ   Russo, Domenico ^t   Petrini, Mario ^u   Milone, Giuseppe ^v   Benedetti, Fabio ^w   Heinzelmann, Marion ^a   Pastore, Domenico ^x   Jurado, Manuel ^j   Terruzzi, Elisabetta ^y   Narni, Franco ^z   Völp, Andreas ^d   Ayuk, Francis ^a   Ruutu, Tapani ^ac   Bonifazi, Francesca ^k   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d Psy Consult Scientific Services   (Germany)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l UNIVERSITY OF UDINE   (Italy)

^m C Arrigo Children's Hospital   (Italy)

ⁿ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^o BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^p CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^q SAN CARLO HOSPITAL   (Italy)

^r CAREGGI UNIVERSITY HOSPITAL   (Italy)

^s S CROCE E CARLE HOSPITAL   (Italy)

^t UNIVERSITY OF BRESCIA   (Italy)

^u UNIVERSITY OF PISA   (Italy)

^v UNIVERSITY OF CATANIA   (Italy)

^w Transfusion Service   (Italy)

^x POLICLINICO   (Italy)

^y SAN GERARDO HOSPITAL   (Italy)

^z UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^aa UNIVERSITY OF SALERNO   (Italy)

^ab SHEBA MEDICAL CENTER   (Israel)

^ac HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOTRANSPLANTATION; CHILD; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMAN; IMMUNOLOGY; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; T LYMPHOCYTE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84954064873     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1506002     Document Type: Article

References (38)

1. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011;29:2230-9.
2. Martin PJ, Counts GW Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010;28:1011-6.
3. Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versushost disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2015;21:266-74.
4. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stemcell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005;23:5074-87.
5. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012;367:1487-96.
6. Passweg JR, Baldomero H, Peters C, et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014;49:744-50.
7. Arora M, Klein JP, Weisdorf DJ, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011;117:6714-20.
8. Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graftversushost disease: a prospective, randomized trial. Blood 1997;89:3880-7.
9. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graftversushost disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989;73:1729-34.
10. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009;10:855-64.
11. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graftversushost disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;98:2942-7.
12. Wolschke C, Zabelina T, Ayuk F, et al. Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation. Bone Marrow Transplant 2014;49:126-30.
13. Bonifazi F, Bandini G, Arpinati M, et al. Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis. Bone Marrow Transplant 2012;47:1105-11.
14. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-33.
15. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56.
16. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versushost disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
17. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562-8.
18. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
19. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
20. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998;17:873-90.
21. Gray RJ. cmprsk: subdistribution analysis of competing risks. 2011 (http://cran. r-project.org/web/packages/cmprsk/index.html).
22. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007;40:381-7.
23. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014;123:3664-71.
24. Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reducedintensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011;117:6963-70.
25. Pavletic SZ, Kumar S, Mohty M, et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant 2010;16:871-90.
26. Storek J, Witherspoon RP, Webb D, Storb R. Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease. Am J Hematol 1996;52:82-9.
27. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991;77:1423-8.
28. Kansu E, Gooley T, Flowers ME, et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft versus host disease: a prospective clinical randomized trial. Blood 2001;98:3868-70.
29. Sullivan KM, Storek J, Kopecky KJ, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996;2:44-53.
30. Kanakry CG, Tsai HL, Bolaños-Meade J, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 2014;124:3817-27.
31. Pasquini MC, Devine S, Mendizabal A, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 2012;30:3194-201.
32. Chakraverty R, Orti G, Roughton M, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood 2010;116:3080-8.
33. Ayuk FA, Fang L, Fehse B, Zander AR, Kröger N. Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. Exp Hematol 2005;33:1531-6.
34. Brüggen MC, Klein I, Greinix H, et al. Diverse T-cell responses characterize the different manifestations of cutaneous graftversushost disease. Blood 2014;123:290-9.
35. Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007;13:6107-14.
36. Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graftversushost disease. Blood 2005;106:2903-11.
37. Fang L, Fehse B, Engel M, Zander AR, Kröger N. Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation 2005;79:369-71.
38. Shimony O, Nagler A, Gellman YN, et al. Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44. J Clin Immunol 2012;32:173-88.